Amundi Has $517.92 Million Holdings in Vertex Pharmaceuticals Incorporated $VRTX

Amundi trimmed its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 63.4% during the second quarter, Holdings Channel.com reports. The firm owned 1,133,226 shares of the pharmaceutical company’s stock after selling 1,965,643 shares during the period. Amundi’s holdings in Vertex Pharmaceuticals were worth $517,918,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Veltria Advisors Corp. raised its holdings in Vertex Pharmaceuticals by 5.6% during the second quarter. Veltria Advisors Corp. now owns 608 shares of the pharmaceutical company’s stock worth $271,000 after buying an additional 32 shares during the last quarter. Great Diamond Partners LLC increased its position in shares of Vertex Pharmaceuticals by 31.3% during the second quarter. Great Diamond Partners LLC now owns 1,776 shares of the pharmaceutical company’s stock worth $791,000 after acquiring an additional 423 shares in the last quarter. Baird Financial Group Inc. raised its holdings in shares of Vertex Pharmaceuticals by 2.4% in the 2nd quarter. Baird Financial Group Inc. now owns 16,392 shares of the pharmaceutical company’s stock worth $7,298,000 after acquiring an additional 391 shares during the last quarter. Knuff & Co LLC lifted its position in Vertex Pharmaceuticals by 1.2% in the 2nd quarter. Knuff & Co LLC now owns 13,996 shares of the pharmaceutical company’s stock valued at $6,231,000 after acquiring an additional 171 shares in the last quarter. Finally, First Trust Advisors LP boosted its stake in Vertex Pharmaceuticals by 98.8% during the 2nd quarter. First Trust Advisors LP now owns 287,892 shares of the pharmaceutical company’s stock valued at $128,170,000 after purchasing an additional 143,084 shares during the last quarter. 90.96% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, Chairman Jeffrey M. Leiden sold 53,604 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Friday, November 14th. The shares were sold at an average price of $440.72, for a total value of $23,624,354.88. Following the completion of the transaction, the chairman directly owned 24,026 shares in the company, valued at approximately $10,588,738.72. The trade was a 69.05% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Stock Performance

Shares of VRTX opened at $457.36 on Friday. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $362.50 and a fifty-two week high of $519.68. The business has a 50-day moving average of $420.74 and a 200 day moving average of $425.42. The firm has a market cap of $116.04 billion, a P/E ratio of 32.25 and a beta of 0.32.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings data on Monday, November 3rd. The pharmaceutical company reported $4.80 EPS for the quarter, beating the consensus estimate of $4.58 by $0.22. The business had revenue of $3.08 billion for the quarter, compared to the consensus estimate of $3.05 billion. Vertex Pharmaceuticals had a net margin of 31.35% and a return on equity of 23.51%. The company’s revenue was up 11.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $4.38 earnings per share. As a group, research analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the company. Wall Street Zen lowered Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Friday, August 22nd. Raymond James Financial assumed coverage on shares of Vertex Pharmaceuticals in a research note on Tuesday, September 2nd. They issued a “market perform” rating for the company. Scotiabank began coverage on shares of Vertex Pharmaceuticals in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $495.00 price target on the stock. Royal Bank Of Canada reduced their price objective on shares of Vertex Pharmaceuticals from $423.00 to $415.00 and set a “sector perform” rating for the company in a research report on Tuesday, November 4th. Finally, UBS Group dropped their target price on shares of Vertex Pharmaceuticals from $553.00 to $546.00 and set a “buy” rating on the stock in a research report on Friday, November 7th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and ten have given a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $495.85.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.